Skip to content

Released Oct 6, 2025, after the close

10-Q filed Nov 13, 2025, 44 days after period end · 0001104659-25-111378

Q3 2025 · 10-Q
Revenue$5.06M+99.0% vs Q3 2024+155.4% vs Q2 2025
Net Income-$7.98MN/M vs Q3 2024N/M vs Q2 2025
EPS Diluted-$0.26N/M vs Q3 2024N/M vs Q2 2025
Gross Profit$3,931,000+119.9%
Operating Income-$8,913,000N/M
Operating Cash Flowderived-$9,614,000N/M
Margins · derived
Gross margin77.7%+7.4 pt vs Q3 2024
Operating margin-176.2%+177.8 pt vs Q3 2024
Net margin-157.7%+210.7 pt vs Q3 2024

What the release said

The release

Same quarter

MetricQ3 2025Q3 2024
Revenue$5.06M$2.54M
Net Income-$7.98M-$9.37M
EPS Diluted-$0.26$0.38

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Profound Medical Corp. · CIK 1628808 · Engraved from SEC EDGAR